Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
Titel:
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
Auteur:
Duffaud, F. Sleijfer, S. Litière, S. Ray-Coquard, I. Le Cesne, A. Papai, Z. Judson, I. Schöffski, P. Chawla, S.P. Dewji, R. Marreaud, S. Verweij, J. van der Graaf, W.T.